Jayendra Patel, MD
Psychiatry · Lake Charles, LANPI 1467434191
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,374 of the $12,522 with a category attached, or 66.9%. Otsuka America Pharmaceutical, Inc. accounts for 79.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $6,407 and has fallen 99.7% since, to $16 in 2024. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $60.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$10K
- Sunovion Pharmaceuticals Inc.$538
- AbbVie$519
- Neurocrine Biosciences, Inc.$416
- Johnson & Johnson$389
- Takeda Pharmaceuticals U.S.A., Inc.$163
- plus $515 from 10 others
What the payments were for
- Speaking & faculty fees$8,37467%
- Travel & lodging$8757%
- Food & beverage$3,27326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 47 | $9,982 |
| Sunovion Pharmaceuticals Inc. | 40 | $538 |
| AbbVie(2 entities) | 35 | $519 |
| Neurocrine Biosciences, Inc. | 19 | $416 |
| Johnson & Johnson | 25 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $163 |
| Alkermes, Inc. | 9 | $139 |
| Vanda Pharmaceuticals Inc. | 8 | $135 |
| Lundbeck LLC | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| Merck | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Lemaitre Vascular, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$9,271
- REXULTI$866
- INGREZZA$125
How this compares
$12,522 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 12 | $296 |
| Risperidone | 27 | $255 |
| Quetiapine Fumarate | 11 | $74 |
| Trazodone Hcl | 15 | $42 |
| Escitalopram Oxalate | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Lake Charles
- Patrick HayesLake Charles$837K
- David MurdockLake Charles$18K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.